Molecular Drivers of Chemoradiation Resistance in Cervical Cancer
Integrated Proteogenomic Study Design
This Hyderabad-based study investigated the molecular basis of chemoradiotherapy resistance in an Indian cervical cancer cohort using 36 tumor tissues with matched blood samples. By integrating Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and LC–MS/MS proteomics, the study explored genomic and proteomic alterations associated with poor response to concurrent chemoradiotherapy (CCRT). The primary goal was to identify resistance-driving biomarkers and therapeutic targets in locally advanced cervical cancer, where nearly 30–40% of patients experience treatment failure.
Genomic Drivers of Chemoradiation Resistance
Genomic profiling uncovered key molecular events driving resistance to chemoradiotherapy in cervical cancer. Frequent PIK3CA mutations activated tumor survival pathways, while KMT2D alterations indicated epigenetic and chromatin instability. Resistant tumors also showed a strong APOBEC mutational signature, highlighting ongoing genomic evolution and heterogeneity.
Notably, resistant cases specifically exhibited EGFR amplification and STK11 deletion, suggesting enhanced proliferative signaling, metabolic rewiring, and therapy adaptation mechanisms that collectively support tumor persistence under CCRT stress.
Multi-Omics Workflow
Patient Cohort → Tumor & Blood Sampling → WGS/WES + LC–MS/MS Profiling → Integrated Multi-Omics Analysis → Biomarker & Resistance Pathway Discovery → Precision Oncology Insights
Multi-Omics Profiling
- Tumor & blood sample analysis
- WGS/WES for genomic alterations
- LC–MS/MS for proteomic profiling
- Integrated analysis of CCRT resistance
Computational & Integrative Analysis
- Comparative analysis of CCRT responders vs non-responders
- Integration of genomic & proteomic alterations
- Identification of resistance pathways & biomarkers
- Key focus: DNA repair | EGFR amplification | STK11 loss | stress-response remodeling
Key Scientific Takeaway
This study demonstrates that chemoradiation resistance in cervical cancer is driven by coordinated genomic and proteomic alterations, including DNA repair activation, oncogenic signaling, and stress-response remodeling. Integrated multi-omics profiling enabled identification of clinically relevant biomarkers such as EGFR, STK11, and STX3 for precision-guided therapeutic strategies.
Through advanced WGS/WES, proteogenomics, and translational bioinformatics analysis, Nucleome Informatics played a key role in interpreting complex multi-omics datasets, uncovering resistance-associated pathways, and accelerating biomarker discovery for precision oncology applications.
Leave a Reply